Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 36 min ago
Peer-reviewedCC BY-NC-ND 4.0Journal of Nanobiotechnology

Precision targeting and regenerative therapies in articular cartilage diseases with AI-driven theranostics

6 affiliations
  1. 1Department of Geriatrics, Shaoxing Seventh People’s Hospital, Affiliated Mental Health Center of Shaoxing University, Shaoxing, China
  2. 2Department of Chemical and Biological Engineering, Iowa State University, 1014 Sweeney Hall, Ames, 50011 Iowa USA
  3. 3Department of Pharmaceutical Engineering, China Pharmaceutical University, 639 Longmian Rd, Nanjing, 211198 China
  4. 4Department of Pharmacology, School of Medicine, Shaoxing University, Shaoxing, China
  5. 5Department of Pharmaceutics, Daqing Branch, Harbin Medical University, 39 Xin Yang Road, Daqing, 163319 China
  6. 6Alberta Institute of Wenzhou Medical University, University Town, Chashan, Wenzhou, 325035 China

Abstract

Arthrochondral disorders affect the cartilage within joints, leading to symptoms such as discomfort, stiffness, and restricted movement. The barrier characteristics, such as the dense, negatively charged extracellular matrix (ECM) and limited vascular pathways, restrict the penetration, retention, and therapeutic performance of intra-articular nanomedicines. This review examines the design of cartilage-specific targeted delivery systems and integrated nanotheranostic systems and critically evaluates the extent to which artificial intelligence (AI) can support nanocarrier formulation, toxicity prediction, imaging analysis, and treatment stratification. This review discusses and analyzes existing research on AI-assisted nanotheranostics for AC diseases following the “barrier–design–validation–transformation” framework, while focusing on current experimental advancements, limitations of existing AI applications, and challenges in clinical implementation. It cannot be denied that AI-assisted nanotheranostic technologies represent a promising approach, but they remain in the emerging stage. Therefore, the evaluation of the clinical value of AI-assisted nanotheranostic technologies depends on standardized datasets, prospective validation, reproducible manufacturing processes, and a robust regulatory framework.

Related

  1. Advanced Nanoemulsion Architectures for Precision Theranostics and Next-Generation Biomedical Translation
    Abhishek Chauhan, Raj Kamal, Mohit Kumar +6
    International Journal of NanomedicinePeer-reviewedCC BY-NC 4.0Full textPharmacology & toxicologyPMC
  2. Immune microenvironment in rotator cuff healing: from macrophage dynamics to immunomodulatory regenerative therapies
    Feng Li, Zhengdao Fu, Xinhai Zhang +2
    Frontiers in bioengineering and biotechnologyPeer-reviewedCC BYFull textSurgery & anaesthesiaEurope PMCPMC
  3. Regenerative therapies in rehabilitation with interfaces with occupational medicine, geriatrics, and oncology: the example of extracorporeal shock wave therapy
    Richard Crevenna
    Wiener Medizinische Wochenschrift (1946)Peer-reviewedCC BY 4.0Full text3 citedSurgery & anaesthesiaPMC
  4. Clinical Response to Regenerative Therapies for Erectile Dysfunction: A Systematic Review and Meta-Analysis of Responder Outcomes
    Rustam Omarbayev, Yerbol Iskakov, Aliya Orassay +3
    Journal of Clinical MedicinePeer-reviewedCC BY 4.0General medicineCrossref
  5. Completeness and guideline concordance of artificial intelligence chatbot responses to patient questions on regenerative therapies for erectile dysfunction: a multi-platform analysis.
    Ethan L Low, Jamie Welsh, Evan Burchfiel +5
    Translational andrology and urologyPeer-reviewedCC BY-NC-NDFull textEpidemiology & public healthEurope PMCPMC
BibTeX
@article{pan2026precision,
  title = {{Precision targeting and regenerative therapies in articular cartilage diseases with AI-driven theranostics}},
  author = {Yue Pan and Yanbo Peng and Jinxia Han and Wenyuan Zhang and Xiaoyu Xu and Man Zhao and Yisheng Xie and Lili Guan and Haisheng Peng and Qun Wang},
  journal = {Journal of Nanobiotechnology},
  year = {2026},
  month = aug,
  doi = {10.1186/s12951-026-04934-w},
  url = {https://doi.org/10.1186/s12951-026-04934-w},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Precision targeting and regenerative therapies in articular cartilage diseases with AI-driven theranostics
AU  - Yue Pan
AU  - Yanbo Peng
AU  - Jinxia Han
AU  - Wenyuan Zhang
AU  - Xiaoyu Xu
AU  - Man Zhao
AU  - Yisheng Xie
AU  - Lili Guan
AU  - Haisheng Peng
AU  - Qun Wang
PY  - 2026
DA  - 2026/08/17
JO  - Journal of Nanobiotechnology
DO  - 10.1186/s12951-026-04934-w
UR  - https://doi.org/10.1186/s12951-026-04934-w
AB  - Arthrochondral disorders affect the cartilage within joints, leading to symptoms such as discomfort, stiffness, and restricted movement. The barrier characteristics, such as the dense, negatively charged extracellular matrix (ECM) and limited vascular pathways, restrict the penetration, retention, and therapeutic performance of intra-articular nanomedicines. This review examines the design of cartilage-specific targeted delivery systems and integrated nanotheranostic systems and critically evaluates the extent to which artificial intelligence (AI) can support nanocarrier formulation, toxicity prediction, imaging analysis, and treatment stratification. This review discusses and analyzes existing research on AI-assisted nanotheranostics for AC diseases following the “barrier–design–validation–transformation” framework, while focusing on current experimental advancements, limitations of existing AI applications, and challenges in clinical implementation. It cannot be denied that AI-assisted nanotheranostic technologies represent a promising approach, but they remain in the emerging stage. Therefore, the evaluation of the clinical value of AI-assisted nanotheranostic technologies depends on standardized datasets, prospective validation, reproducible manufacturing processes, and a robust regulatory framework.
SN  - 1477-3155
ER  -